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Abstract
Src family kinases (SFKs) have been implicated in resistance to both radiation and epidermal growth factor receptor
(EGFR) inhibition. Therefore, we investigatedwhether inhibition of SFK through dasatinib (DSB) can enhance the effect
of radiotherapy in two in vivo human head and neck squamous cell carcinoma (HNSCC) models. Response to DSB
and/or radiotherapy was assessed with tumor growth delay assays in two HNSCC xenograft models, SCCNij153 and
SCCNij202. Effects on EGFR signaling were evaluated withWestern blot analysis, and effects on DNA repair, hypoxia,
and proliferation were investigated with immunohistochemistry. DSB and radiotherapy induced a significant growth
delay in both HNSCC xenograft models, although to a lesser extent in SCCNij202. DSB did not inhibit phosphorylated
protein kinase B (pAKT) or phosphorylated extracellular signal–regulated kinase 1/2 (pERK1/2) but did inhibit (phos-
phorylated) DNA-dependent protein kinase. Moreover, DSB reduced repair of radiation-induced DNA double-strand
breaks as shown by an increase of p53-binding protein 1 (53BP1) staining 24 hours after radiation. This effect on
DNA repair was only observed in the cell compartment where phosphorylated SFK (pSFK) was expressed: for
SCCNij153 tumors in both normoxic and hypoxic areas and for SCCNij202 tumors only in hypoxic areas. No consistent
effects of DSB on hypoxia or proliferation were observed. In conclusion, DSB enhances the effect of radiotherapy
in vivo by inhibition of radiation-induced DNA repair and is a promising way to improve outcome in HNSCC patients.
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Introduction
Overexpression of the epidermal growth factor receptor (EGFR) is a
frequent event in head and neck squamous cell carcinoma (HNSCC)
and is associated with a worse prognosis after radiotherapy [1]. Accord-
ingly, a randomized clinical trial has shown that addition of cetuximab,
a chimeric monoclonal antibody against the extracellular part of
EGFR, improves the clinical outcome in HNSCC patients treated
with radiotherapy [2]. However, locoregional control at 3 years was
only improved from 34% in the group treated with radiotherapy alone
to 47% in the group treated with radiotherapy and cetuximab com-
bined, while most patients experienced additional side effects due to
the addition of cetuximab [2]. Hence, to further improve outcome
in these patients, it will be essential to develop therapeutic strategies
that target other molecules of the EGFR signaling network involved
in resistance to radiotherapy.
Src family kinases (SFKs) are non-receptor kinases involved in path-
ways that control cell division, motility, adhesion, angiogenesis, and
survival [3,4]. It has been shown that SFKs interact with growth factor
signaling, including signaling through EGFR [5–7]. More importantly,
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activated SFKs are required for the nuclear translocation of EGFR
induced by cetuximab or radiation [8,9]. Nuclear EGFR increases
DNA repair through interaction with DNA-dependent protein kinase
(DNA-PK) and consequently decreases radiosensitivity [10]. Al-
though radiation-induced translocation of EGFR to the nucleus can
be blocked by cetuximab [11], nuclear EGFR is also a cause of resistance
to cetuximab [12]. Therefore, inhibition of nuclear EGFR through
inhibition of SFKs could enhance radiosensitivity by decreasing repair
of radiation-induced DNA damage.
Activity of SFKs can be inhibited by dasatinib (DSB), a small
molecule tyrosine kinase inhibitor that also inhibits other kinases,
including ABL [13]. DSB inhibits the in vitro growth of different
tumor lines [13], including head and neck cancer lines [14]. However,
SFK inhibition does not seem to have large effects on tumor growth
in vivo [15,16] and also the clinical efficacy of DSB as a single agent
in HNSCC seems low despite effective c-Src inhibition [17]. Never-
theless, the important role of SFKs in growth factor signaling and
nuclear translocation of EGFR makes DSB an interesting candidate
for enhancing the efficacy of radiotherapy in HNSCC. A recent study
by Raju et al. [18] has indeed shown that DSB enhances radiosensitivity
in HNSCC cells in vitro through inhibition of nuclear EGFR and by
decreasing radiation-induced DNA repair. However, the tumor micro-
environment, which exposes tumor cells to fluctuating oxygen and
nutrient gradients, can have a great impact on tumor behavior and
tumor response. Therefore, it is of great importance to determine the
effects of DSB and radiotherapy in the context of the tumor micro-
environment in in vivo models before these results can be translated
to the clinic.
In this study, we investigated the potential of combining DSB
with radiotherapy in vivo by analyzing the effects of DSB and radio-
therapy on tumor growth, EGFR signaling, and DNA repair in two
human HNSCC xenograft models. These HNSCC models both
show high EGFR expression [19] but differ in their expression level
of phosphorylated SFK (pSFK). In addition, the effects on hypoxia
and proliferation, two important mechanisms involved in resistance
to radiotherapy, were examined.
Materials and Methods
Xenograft Tumor Models and Treatment
Tumor models SCCNij153 and SCCNij202 were derived from
human larynx carcinomas. Viable 1-mm3 tumor pieces were implanted
subcutaneously in 6- to 10-week-old athymic BALB/c nu/nu mice and
passaged at a diameter of 1 cm. Tumors with a mean diameter of 4 to
5 mm transplanted at the hind leg were used in the experiments.
Animals were treated with DSB (70 mg/kg per day, oral; LC Labora-
tories,Woburn,MA) for 5 days, 10Gy single-dose radiotherapy (320 kV,
dose rate of 3.8 Gy/min, X-RAD; RPS Services Limited, Surrey,
United Kingdom), or a combination of DSB and 10 Gy radiotherapy
(given on day 4 of DSB treatment).
For effects on tumor growth delay, tumor diameters were measured
twice a week in three perpendicular directions and tumor volumes were
determined by the following formula: V = (a * b * c * π)/6. Endpoint
was reached when the tumor volume tripled compared to the volume
at start of treatment. Maximal follow-up was 60 days.
For effects on protein expression, proliferation, and hypoxia, tumors
were harvested 1 day after 10 Gy radiotherapy and/or on day 5 of
DSB treatment. One hour before euthanasia, animals were injected
with 80 mg/kg of the hypoxia marker pimonidazole hydrochloride
(1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride;
Natural Pharmaceuticals International Inc, Research Triangle Park,
NC) and 15 minutes before euthanasia with 50 mg/kg of the prolifer-
ation marker bromodeoxyuridine (BrdU; Sigma, St Louis, MO). After
excision, tumors were snap frozen in liquid nitrogen.
Animals were kept in a specific pathogen-free unit in accordance
with institutional guidelines. All experiments were approved by the
Animal Experiments Committee of the Radboud University Nijmegen
Medical Centre.
Western Blot Analysis
Tumor sections were lysed inNP-40 lysis buffer and protein was quan-
titated using a standard Bradford absorbance assay. Proteins (35 μg
per lane) were separated by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and blotted onto polyvinylidene fluoride (PVDF) mem-
brane. Membranes were incubated with the appropriate primary anti-
bodies followed by incubation with HRP-conjugated antibodies and
proteins were detected with an ECL chemiluminescence system. Anti-
bodies against the following antigens were used: EGFR, protein kinase B
(AKT), and HRP-conjugated goat anti-mouse IgG were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). DNA-PK, phos-
phorylated DNA-PK (pDNA-PK, S2056), SFK, (pSFK, Y416),
phosphorylated protein kinase B (pAKT; S473), extracellular signal–
regulated kinase 1/2 (ERK1/2), phosphorylated extracellular signal–
regulated kinase 1/2 (pERK1/2; T202/Y204), and HRP-conjugated
goat anti-rabbit IgG were purchased from Cell Signaling Technology
(Beverly, MA), and α-tubulin was obtained from Calbiochem (San
Diego, CA).
Immunohistochemical Staining
For quantification of hypoxia and proliferation, frozen tumor sec-
tions (5 μm) were stained for pimonidazole and BrdU, respectively,
vessels and nuclei. For quantification of DNA damage, tumor sec-
tions were stained for p53-binding protein 1 (53BP1) or Rad51,
pimonidazole, vessels, and nuclei. To evaluate colocalization of pSFK
and hypoxia, tumor sections were stained for pSFK (Y416), pimoni-
dazole, and vessels.
The antibody against pimonidazole was a gift from J. A. Raleigh
(University of North Carolina). Vessels were detected with 9F1, a rat
monoclonal antibody against mouse endothelium (Department of
Pathology, Radboud University Nijmegen Medical Centre). The anti-
body against BrdU was purchased from Genetex (Irvine, CA), antibody
against 53BP1 from Thermo Scientific (Waltham, MA), and the anti-
body against Rad51 from Epitomics (Burlingame, CA).
Primary antibodies were detected by appropriate Cy3-conjugated
(Jackson ImmunoResearch Laboratories Inc, West Grove, PA), Alexa
488–, Alexa 647–, or Alexa 55–conjugated (Molecular Probes, Leiden,
The Netherlands) secondary antibodies. All secondary antibodies
were tested for specificity for the primary antibody by performing
the staining procedures without the primary antibody. Nuclei were
stained with Hoechst 33342 (Sigma) or 4′,6-diamidino-2-phenylindole
(DAPI; Abcam, Cambridge, United Kingdom).
Image Acquisition and Computerized Analysis of DNA Repair
Approximately eight single fields were randomly chosen and re-
corded in tumor sections stained for 53BP1 or Rad51 using a fluo-
rescence microscope (Zeiss, Göttingen, Germany). Each single field
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was acquired with different filters at ×400 magnification to yield images
of the different fluorescent signals. Single fields were acquired in both
normoxic and hypoxic tumor areas based on pimonidazole staining.
Gray value images of 53BP1, Rad51, and nuclei were converted to
binary images by setting thresholds for the fluorescence signals above
the background using ImageJ software (NIH, Bethesda, MD). Hypoxic
tumor areas were delineated using the pimonidazole gray value images.
The nuclear area positive for 53BP1 or Rad51 and the number of
nuclei were quantified in hypoxic and normoxic regions separately.
The average area positive for 53BP1 or Rad51 per nucleus was calcu-
lated by dividing the total nuclear area of 53BP1 or Rad51 by the total
number of nuclei. At least 600 nuclei per tumor section were analyzed.
Image Acquisition and Computerized Analysis of Hypoxia
and Proliferation
Stained tumor sections were scanned with a fluorescence microscope
(Zeiss). Each section was sequentially scanned at ×100 magnification
to yield images of the different fluorescent signals. Thresholds for the
fluorescence signals were interactively set above the background and
the gray value images were converted to binary images. The hypoxic
fraction (HF) was calculated by dividing the tumor area positive for
pimonidazole by the total tumor area and the BrdU labeling index
(LI) by dividing the nuclear area positive for BrdU by the total nuclear
area of the tumor, as described before [20,21]. Necrotic areas and stain-
ing artifacts were excluded from analysis.
Statistics
Tumor growth delay data were analyzed using Kaplan-Meier survival
curves and Cox proportional-hazards regression. To determine whether
DSB and radiotherapy had a synergistic effect on growth delay, the
relative excess risk due to interaction (RERI) was calculated as described
by Andersson et al. [22]. RERI values above 0 indicate biologic inter-
action between treatments.
Changes in hypoxia, proliferation, and DNA damage after treat-
ment were tested for significance using unpaired t tests. All tests were
performed using Prism (GraphPad Software, Inc, La Jolla, CA), and
P values < .05 were considered significant.
Results
Combining DSB with Radiotherapy Induces Significantly
Enhanced Growth Delay in HNSCC Xenograft Tumors
SCCNij153 and SCCNij202 tumors both expressed high levels of
EGFR and phosphorylated EGFR (pEGFR), indicating active EGFR
signaling in these tumor models (Figure 1A). SFKs and their activated
forms were also expressed in both tumor models, although the level of
pSFK was markedly lower in SCCNij202 tumors (Figure 1A).
In both SCCNij153 and SCCNij202, the combination of DSB
and radiotherapy significantly delayed tumor growth compared to
untreated tumors (P < .05), while DSB or radiotherapy alone did not
induce a significant delay (Figure 1B). These results indicate a syner-
gistic effect of DSB and radiotherapy, and RERI values of 2.0 and
0.70 for SCCNij153 and SCCNij202, respectively, confirm this inter-
action. Although significant, the absolute delay in growth was small
in SCCNij202 tumors, as is also reflected by the relative low RERI
value of 0.70.
DSB Inhibits DNA-PK but Not AKT or ERK Signaling
Using Western blot analyses, clear inhibition of pSFK was observed
in both tumor models when tumors were treated with DSB or the
combination of DSB and radiotherapy (Figure 2). DSB also decreased
EGFR in SCCNij202 tumors but not in SCCNij153 tumors, while
DSB slightly decreased pAKT in SCCNij153 tumors. However,
no large effects on pAKT or pERK1/2 levels were observed in both
tumor models after radiotherapy, DSB, or combined treatment. In
Figure 1. Expression of EGFR and pSFK and effects of DSB and/or radiotherapy on tumor growth delay. (A) Expression of (p)EGFR and
(p)SFK in untreated SCCNij153 and SCCNij202 tumors. Two tumors per line were analyzed and both tumor lines were blotted on the
same membrane. α-Tubulin was used as loading control. (B) Kaplan-Meier survival curves showing the effect of DSB and/or radiotherapy
on the tumor growth of SCCNij153 and SCCNij202. Events were scored when the tumor volume tripled compared to the start volume
and % tumor response represents the percentage of tumors that did not reach the event. Tumors were treated with DSB (five times
70 mg/kg), 10 Gy radiotherapy, or combined DSB and radiotherapy. Number of animals per group: six to eight.
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contrast, DNA-PK levels were clearly decreased by DSB in both tumor
models. Activated DNA-PK (pDNA-PK) was also inhibited by DSB in
SCCNij202 tumors, although variation was present in tumors treated
with combined DSB-radiotherapy treatment. In SCCNij153 tumors,
pDNA-PK levels were non-detectable and effects of treatment could
not be assessed.
DSB Increases Residual DNA Damage after Radiotherapy but
Only in the Tumor Compartment Where pSFK Is Expressed
To determine whether decreased DNA-PK levels resulted in reduced
repair of DNA double strand breaks, tumors were harvested 24 hours
after radiotherapy with and without DSB and immunofluorescently
stained for 53BP1. In SCCNij153 tumors, the area of 53BP1 per
nucleus increased when DSB was combined with radiotherapy com-
pared to radiotherapy alone in both hypoxic and normoxic tumor
regions (P < .01; Figure 3A). This indicates increased residual DNA dam-
age and thus a reduction of DNA repair due to DSB. In SCCNij202
tumors, only hypoxic regions showed increased 53BP1 staining after
addition of DSB (P < .01).
Rad51 staining was also analyzed to determine the effects on DNA
repair by homologous recombination (HR; Figure 3B). Again, the
Rad51 area was increased in both hypoxic (n.s.) and normoxic (P <
.05) regions of SCCNij153 tumors treated with DSB and radiotherapy
compared to radiotherapy alone, while in SCCNij202 this effect of
DSB was only observed in hypoxic regions (P < .01).
The hypoxia-specific effects of DSB in SCCNij202 tumors could
be due to a higher expression of pSFK under influence of hypoxia in
this tumor model. Therefore, untreated tumors of both SCCNij153
and SCCNij202 were immunofluorescently stained for pSFK and
hypoxia (Figure 4). In SCCNij153, pSFK was widely expressed in both
Figure 3. Effects of DSB and/or radiotherapy on residual DNA damage. Average area positive for 53BP1 (A) or Rad51 (B) per nucleus in
untreated tumors and tumors harvested 24 hours after treatment with radiotherapy (10 Gy) or DSB (five times 70 mg/kg) and radiotherapy.
Differences between 10 Gy and DSB + 10 Gy in hypoxic or normoxic areas were tested for significance using t tests, *P < .05, **P < .01.
Error bars represent SEM. Number of animals per group: three to four.
Figure 2. Effects of DSB and/or radiotherapy on EGFR signaling.
Expression of EGFR, pSFK, (p)AKT, (p)ERK1/2, and (p)DNA-PK in
SCCNij202 and SCCNij153 tumors. α-Tubulin was used as loading
control. Tumors were treated with DSB (five times 70 mg/kg), 10 Gy
radiotherapy, or combined DSB and radiotherapy. Tumors were
harvested 24 hours after radiotherapy or after the fifth DSB treatment.
Three tumors per line were analyzed and tumor lines were blotted
on separate membranes.
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normoxic and hypoxic regions of the tumor, while pSFK expression
in SCCNij202 tumors was restricted to hypoxic regions of the tumor.
This difference in pSFK expression pattern between SCCNij153 and
SCCNij202 is also reflected in total pSFK levels of these tumors as
observed with Western blot (Figure 1A).
Hence, these data indicate that DSB reduces radiation-induced
DNA repair and that this effect is restricted to regions of the tumor
where pSFK is expressed.
No Effect of DSB on Hypoxia or Proliferation
No consistent effects of DSB on hypoxia or proliferation were
observed (Figure 5). Only the combination of DSB and radiotherapy
reduced proliferation significantly in SCCNij202 (P < .05), while
DSB alone did not induce any reduction in proliferation.
Discussion
In the present study, we show that DSB enhances the effect of radio-
therapy in two HNSCC xenograft models with EGFR expression.
Moreover, we show that this interaction is likely due to inhibition of
pSFK-mediated activation of DNA-PK by DSB, resulting in increased
residual DNA damage after radiotherapy. However, the effects on
tumor growth delay and DNA repair differed between tumor models,
which has important implications for further research.
Figure 4. Expression of pSFK in relation to hypoxia in SCCNij153 and SCCNij202. Expression of pSFK in relation to hypoxia was visualized
by immunofluorescence staining in untreated SCCNij153 and SCCNij202 tumors. pSFK, red; hypoxia, green; vessels, blue. Non-specific
staining present in necrotic regions. Scale bars represent 500 μm. Original magnification, ×200.
Figure 5. Effects of DSB and/or radiotherapy on proliferation and hypoxia. Effects of DSB and/or radiotherapy on the BrdU LI (A) and
hypoxic fraction (HF; B). Tumors were treated with DSB (five times 70 mg/kg), 10 Gy radiotherapy, or combined DSB and radiotherapy.
Tumors were harvested 24 hours after radiotherapy or after the fifth DSB treatment. Differences between treatment groups were tested
for significance using t tests, *P < .05. Error bars represent SEM. Number of animals per group: three to four.
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DSB has earlier been shown to induce degradation of EGFR and
consequently inhibition of downstream pAKT and pERK1/2, re-
sulting in induction of apoptosis in HNSCC in vitro [23]. In addition,
Raju et al. reported that DSB only enhances radiation sensitivity in
HNSCC cell lines in which DSB reduces pAKT levels [18]. Moreover,
activation of AKT by radiation has been observed in various in vitro
models, while Kim et al. established that c-Src signaling is involved
in this activation of AKT [24]. Although EGFR levels were slightly
reduced after DSB treatment in SCCNij202, we neither observed
activation of pAKT or pERK1/2 after radiation nor inhibition of pAKT
or pERK1/2 after DSB treatment. This lack of change in pAKT and
pERK1/2 levels could be due to activating factors present in our in vivo
tumor models that are not present in the in vitro cell culture conditions
applied by others [18,23,24]. In the study of Lin et al., cells can be
rescued from DSB-induced apoptosis by increasing EGFR activation
through ligand administration [23]. We did not measure EGFR ligand
levels, but as both tumor models show high phosphorylated EGFR
levels, it is likely that these ligands are indeed present in our tumor
models. In addition, we have shown that in vivo expression of these
kinases can be substantially affected by the tumor microenvironment
[25]. The lack of inhibition of pERK1/2 and pAKT by DSB is also
consistent with the observation that DSB alone did not have an effect
on growth delay in either of our tumor models.
In contrast to pAKT and pERK1/2, we did observe significant
inhibition of DNA-PK by DSB. In addition, pDNA-PK levels were
decreased in SCCNij202 tumors treated with DSB. In SCCNij153
tumors, pDNA-PK levels were below the detection limits and we could
not confirm inhibition by DSB in this tumor model. Western blot
analysis of whole tumor lysates also includes non-tumor tissue and this
could decrease the expression levels of tumor proteins. This can make
detection of proteins expressed at very low levels, like pDNA-PK, very
difficult. EGFR signaling has been shown to affect DNA-PK activity by
two ways, i.e., by indirect activation through the phosphatidylinositol
3-kinase (PI3-K)-AKT pathway (cytoplasmic pathway) or by direct
interaction between EGFR and DNA-PK after translocation of EGFR
to the nucleus (nuclear pathway) [26]. pSFK is involved in the nuclear
translocation of EGFR and our observations that DNA-PK is inhibited
by DSB independent of pAKT levels suggests that DSB blocks only the
nuclear signaling pathway of EGFR in our tumor models but not the
cytoplasmic pathways.
Importantly, we further observed that irradiated tumors that also
received DSB showed an increase in residual DNA damage as detected
by 53BP1 staining, which indicates that the inhibition of DNA-PK
resulted in a functional reduction of DNA repair. Hence, our data
indicate that DSB enhances radiosensitivity in vivo by inhibition of
radiation-induced DNA repair. DNA double strand breaks can be re-
paired through two main pathways: non-homologous end joining
and HR [27]. DNA-PK is a key protein of non-homologous end join-
ing, which acts throughout the cell cycle and repairs the majority of all
DNA double strand breaks. However, we also observed an effect of
DSB on radiation-reduced repair through HR as we detected increased
levels of Rad51, a key protein in HR. Inhibition of EGFR signaling has
been shown to regulate HR, but this seems to be regulated through the
cytoplasmic and not the nuclear pathway of EGFR [28].
HR acts only in S and G2 phases of the cell cycle. The observed
effect of DSB on HR cannot, however, be explained by changes in cell
cycle distribution. No effects on proliferation by DSB were observed
in SCCNij153, and although combined DSB-radiotherapy did
decrease proliferation in SCCNij202 compared to untreated tumors,
a decrease in proliferation should result in a decrease in Rad51 and not
an increase as we observed. Several other mechanisms could explain
the effect of DSB on HR. It has been shown that inhibition of
DNA-PK activity increases the activity of HR, suggesting that the
observed increase in Rad51 is due to a compensatory increase of
double strand breaks repaired through HR [29]. Lastly, DSB targets
many kinases and the effect on HR could be independent of pSFK
inhibition. Nonetheless, the observation that the effect of DSB on
DNA repair was only present in the tissue compartment where
pSFK is expressed does suggest that pSFK is involved in the effect on
DNA repair.
We observed striking differences in the expression pattern of pSFK
between the two tumor models. pSFK was expressed diffusely through-
out the tumors in SCCNij153 and only expressed in hypoxic regions
in SCCNij202. This differential expression pattern probably explains
the smaller effect of DSB on growth delay in SCCNij202 as only the
hypoxic cells could be targeted by DSB in this tumor model. Both
in vitro and in vivo studies have shown that pSFK is involved in the
hypoxic response of tumor cells and is important for cell survival under
hypoxic conditions [30,31]. The hypoxia-dependent expression of
pSFK in SCCNij202 thus seems a more “physiological” response, while
the diffuse expression in SCCNij153 indicates constitutive activation of
SFKs, which can arise through multiple mechanisms [3]. Hence, the
expression pattern of pSFK could be an important predictive biomarker
for response to combined treatment with DSB and radiotherapy.
Next to lower pSFK expression, the modest growth delay in
SCCNij202 is also due to large variation in growth delay that was in-
duced by DSB and radiotherapy in this tumor model; some tumors
reached the endpoint at time points comparable to controls, while
other tumors showed a clear growth delay. In addition, the variation
in pDNA-PK levels between tumors treated with DSB and radio-
therapy demonstrates the variation in response to treatment. This
variation is probably also due to the hypoxia-related expression pattern
of pSFK in this tumor model. This expression pattern suggests that
tumors with a higher HF will have a higher pSFK fraction. Although
we treated all tumors at approximately the same volume, the extent of
hypoxia varied between these tumors. Using immunofluorescence, we
did indeed observe that untreated tumors with a higher HF also had a
higher pSFK fraction (data not shown), although the number of tumors
is too low to draw firm conclusions. Together, these data suggest that
tumors with a higher HF have a higher fraction of cells that can be
targeted by DSB, resulting in a larger effect on tumor growth. Thus,
even tumors of the same tumor model can differ significantly in their
response due to small differences in tumor microenvironmental param-
eters. DSB itself did not affect microenvironmental characteristics that
are relevant for radiosensitivity, i.e., hypoxia and proliferation. The
combination of DSB and radiotherapy only reduced proliferation in
SCCNij202 tumors. However, as we measured tumor cell prolifera-
tion only at 24 hours after radiotherapy, we possibly missed the effect
of DSB and radiotherapy on proliferation in SCCNij153 tumors. At
24 hours after radiotherapy, there can be BrdU labeling of cells that
are doomed to die after one or two cell divisions and effects due to
these doomed cells cannot be excluded.
In conclusion, DSB has the potential to enhance the efficacy of
radiotherapy in vivo by inhibition of radiation-induced DNA repair.
DSB is thus a promising additive to radiotherapy to improve outcome
in patients. However, the extent of effects differed between tumor
models and further investigation is warranted to determine which
tumor characteristics are predictive for response (e.g., EGFR and pSFK
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expression levels, HF). Addition of another kinase inhibitor, like a
pAKT inhibitor, which blocks cytoplasmic pathways important for
radiation resistance could enhance outcome even further. This knowl-
edge will be critical for optimal use of the combination of DSB and
radiotherapy in the clinic.
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